IBEX 35
11.211,70 +59,70 (+0,54%) Euro Stoxx 50
5.073,24 -5,72 (-0,11%) Dólar/Euro
1,0814 +0,0021 (+0,19%) Petróleo Brent
83,00 -0,36 (-0,43%) Oro
2.356,80 +13,80 (+0,59%) Bitcoin EUR
56.537,06 -1.734,06 (-2,98%)
MyMD Pharmaceuticals, Inc. (0A8D.L)
MyMD Pharmaceuticals, Inc.
855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
(856) 848-8698
https://www.mymd.com
Sector(es):
Sector:
Empleados a tiempo completo: 6
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | President, Chief Medical Officer & Director | 665,76k | N/A | 1953 |
| Mr. Ian Rhodes CPA | Interim Chief Financial Officer | 162k | N/A | 1973 |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development | N/A | N/A | N/A |
Descripción
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immunometabolic system and its pro-inflammatory cytokines to treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Gobierno corporativo
El ISS Governance QualityScore de MyMD Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
